Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: A 26-week, multicenter, open-label study

American Journal Geriatric Pharmacotherapy

Volumn 3, Issue 3, 2005, Pages 137-148

  Cummings, Jeffrey L ^a   Koumaras, Barbara ^b   Chen, Michael ^b   Mirski, Dario ^b   Binder, Ellen ^c   Folstein, Marshal ^d   Zayas, Elsa M ^e   Ownby, Raymond ^f   Merideth, Charles H ^g   Scharre, Douglas W ^h   Tariot, Pierre ⁱ   Edwards, Keith ^j   Aupperle, Peter M ^k   Ellis, Jay M ^l   Pahl, Jorg J ^m   Kiev, Ari ⁿ  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d TUFTS MEDICAL CENTER   (United States)

^e S LOUIS UNIV HLTH SCIENCES CENTER   (United States)

^f UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^g Research Institute   (United States)

^h OHIO STATE UNIVERSITY   (United States)

ⁱ Monroe Community Hospital   (United States)

^j Alzheimers Diagnostic Center   (United States)

^k UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^l Berkshire Associates   (United States)

^m Pahl Brain Associates   (United States)

ⁿ Social Psychiatry Research Institute   (United States)

more..

Author keywords

Alzheimer's disease; Behavioral disturbances; Cognitive impairment; Dementia; Nursing home; Rivastigmine

Indexed keywords

RIVASTIGMINE;

ABRASION; AGED; AGING; AGITATION; ALZHEIMER DISEASE; ANOREXIA; APATHY; APPETITE DISORDER; ARTICLE; BEHAVIOR DISORDER; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DEHYDRATION; DELUSION; DEMENTIA; DISEASE EXACERBATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FALLING; FEMALE; FRACTURE; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NURSING HOME; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOPATHY; RATING SCALE; SEPSIS; SIDE EFFECT; SKIN BRUISING; SKIN INJURY; SOLID TUMOR; TREATMENT OUTCOME; UNITED STATES; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BEHAVIORAL SYMPTOMS; CHOLINESTERASE INHIBITORS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HOMES FOR THE AGED; HUMANS; INPATIENTS; MALE; NEUROPROTECTIVE AGENTS; NEUROPSYCHOLOGICAL TESTS; NEUROTIC DISORDERS; NURSING HOMES; PHENYLCARBAMATES; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 27844431640     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1543-5946(05)80020-0     Document Type: Article

References (49)

1. Barker WW Luis CA Kashuba A et al. Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank Alzheimer Dis Assoc Disord 16 2002 203-212
2. Cummings JL Neuropsychiatry of Alzheimer's Disease and Related Disorders 2003 Martin Dunitz London
3. Lyketsos CG Lopez O Jones B et al. Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: Results from the cardiovascular health study JAMA 288 2002 1475-1483
4. Lyketsos CG Steinberg M Tschanz JT et al. Mental and behavioral disturbances in dementia: Findings from the Cache County Study on Memory in Aging Am J Psychiatry 157 2000 708-714
5. Mega MS Cummings JL Fiorello T Gornbein J The spectrum of behavioral changes in Alzheimer's disease Neurology 46 1996 130-135
6. Rymer S Salloway S Norton L et al. Impaired awareness, behavior disturbance, and caregiver burden in Alzheimer disease Alzheimer Dis Assoc Disord 16 2002 248-253
7. Schulz R Martire LM Family caregiving of persons with dementia: Prevalence, health effects, and support strategies Am J Geriatr Psychiatry 12 2004 240-249
8. Gilley DW McCann JJ Bienias JL Evans DA Caregiver psychological adjustment and institutionalization of persons with Alzheimer's disease J Aging Health 17 2005 172-189
9. Yaffe K Fox P Newcomer R et al. Patient and caregiver characteristics and nursing home placement in patients with dementia JAMA 287 2002 2090-2097
10. Margallo-Lana M Swann A O'Brien J et al. Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments Int J Geriatr Psychiatry 16 2001 39-44
11. Rovner BW German PS Broadhead J et al. The prevalence and management of dementia and other psychiatric disorders in nursing homes Int Psychogeriatr 2 1990 13-24
12. Draper B Brodaty H Low LF et al. Use of psychotropics in Sydney nursing homes: Associations with depression, psychosis, and behavioral disturbances Int Psychogeriatr 13 2001 107-120
13. Cummings JL Donohue JA Brooks RL The relationship between donepezil and behavioral disturbances in patients with Alzheimer's disease Am J Geriatr Psychiatry 8 2000 134-140
14. Cummings JL Kaufer D Neuropsychiatric aspects of Alzheimer's disease: The cholinergic hypothesis revisited Neurology 47 1996 876-883
15. Wynn ZJ Cummings JL Cholinesterase inhibitor therapies and neuropsychiatric manifestations of Alzheimer's disease Dement Geriatr Cogn Disord 17 2004 100-108
16. Sink KM Holden KF Yaffe K Pharmacological treatment of neuropsychiatric symptoms of dementia: A review of the evidence JAMA 293 2005 596-608
17. Courtney C Farrell D Gray R et al. for the AD2000 Collaborative Group Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): Randomised double-blind trial Lancet 363 2004 2105-2115
18. Tariot PN Cummings JL Katz IR et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting J Am Geriatr Soc 49 2001 1590-1599
19. Ballard C Margallo-Lana M Juszczak E et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: Randomised double blind placebo controlled trial BMJ 330 2005 874
20. Enz A Amstutz R Boddeke H et al. Brain selective inhibition of acetylcholinesterase: A novel approach to therapy for Alzheimer's disease Prog Brain Res 98 1993 431-438
21. Corey-Bloom J Anand R Veach J A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease Int J Geriatr Psychopharmacol 1 1998 55-65
22. Rosler M Anand R Cicin-Sain A et al. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial [published correction appears in BMJ. 2001;322:1456] BMJ 318 1999 633-638
23. McKhann G Drachman D Folstein M et al. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease Neurology 34 1984 939-944
24. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders Fourth Edition 1994 American Psychiatric Association Washington, DC
25. Folstein MF Folstein SE McHugh PR "Mini-mental state." A practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 12 1975 189-198
26. Rosen WG Terry RD Fuld PA et al. Pathological verification of ischemic score in differentiation of dementias Ann Neurol 7 1980 486-488
27. Wood S Cummings JL Hsu MA et al. The use of the neuropsychiatric inventory in nursing home residents. Characterization and measurement Am J Geriatr Psychiatry 8 2000 75-83
28. Rosen WG Mohs RC Davis KL A new rating scale for Alzheimer's disease Am J Psychiatry 141 1984 1356-1364
29. Schneider LS Olin JT Doody RS et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study Alzheimer Dis Assoc Disord 11 Suppl 2 1997 22-32
30. Cummings JL Gorman DG Shapira J Physostigmine ameliorates the delusions of Alzheimer's disease Biol Psychiatry 33 1993 536-541
31. Kaufer DI Cummings JL Christine D Effect of tacrine on behavioral symptoms in Alzheimer's disease: An open-label study J Geriatr Psychiatry Neurol 9 1996 1-6
32. Morris JC Cyrus PA Orazem J et al. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease Neurology 50 1998 1222-1230
33. Raskind MA Cyrus PA Ruzicka BB Gulanski BI for the Metrifonate Study Group The effects of metrifonate on the cognitive, behavioral, and functional performance of Alzheimer's disease patients J Clin Psychiatry 60 1999 318-325
34. Raskind MA Sadowsky CH Sigmund WR et al. Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer disease Arch Neurol 54 1997 836-840
35. Tariot PN Solomon PR Morris JC et al. for the Galantamine USA-10 Study Group A 5-month, randomized, placebo-controlled trial of galantamine in AD Neurology 54 2000 2269-2276
36. Bodick NC Offen WW Levey AI et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease Arch Neurol 54 1997 465-473
37. Levy ML Cummings JL Kahn-Rose R Neuropsychiatric symptoms and cholinergic therapy for Alzheimer's disease Gerontology 45 Suppl 1 1999 15-22
38. Ballard CG Advances in the treatment of Alzheimer's disease: Benefits of dual cholinesterase inhibition Eur Neurol 47 2002 64-70
39. Mesulam M Neuroanatomy of cholinesterases in the normal human brain and in Alzheimer's disease In Giacobini E ed. Cholinesterase and Cholinesterase Inhibitors 2000 Martin Dunitz London 121-137
40. Wright CI Geula C Mesulam MM Neurological cholinesterases in the normal brain and in Alzheimer's disease: Relationship to plaques, tangles, and patterns of selective vulnerability Ann Neurol 34 1993 373-384
41. Anand R Gharabawi M Enz A Efficacy and safety results of the early phase studies with Exelon® (ENA-713) in Alzheimer's disease: An overview J Drug Dev Clin Pract 8 1996 109-116
42. Fishman EB Siek GC MacCallum RD et al. Distribution of the molecular forms of acetylcholinesterase in human brain: Alterations in dementia of the Alzheimer type Ann Neurol 19 1986 246-252
43. Siek GC Katz LS Fishman EB et al. Molecular forms of acetylcholinesterase in subcortical areas of normal and Alzheimer disease brain Biol Psychiatry 27 1990 573-580
44. Nordberg A The effect of cholinesterase inhibitors studies with brain imaging In Giacobini E ed. Cholinesterase and Cholinesterase Inhibitors 2000 Martin Dunitz London 237-247
45. Potkin SG Anand R Fleming K et al. Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease Int J Neuropsychopharmacol 4 2001 223-230
46. McKeith I Del Ser T Spano P et al. Efficacy of rivastigmine in dementia with Lewy bodies: A randomised, double-blind, placebo-controlled international study Lancet 356 2000 2031-2036
47. Reading PJ Luce AK McKeith IG Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: Preliminary findings from an open trial Mov Disord 16 2001 1171-1174
48. Emre M Aarsland D Albanese A et al. Rivastigmine for dementia associated with Parkinson's disease N Engl J Med 351 2004 2509-2518
49. Billig N Alzheimer's disease. A psychiatrist's perspective Nurs Clin North Am 23 1988 125-133